Candel Therapeutics, Inc. SEC filings CADL
Candel Therapeutics, Inc. has 418 filings in SEC EDGAR's recent list, going back to Feb 16, 2021. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 15, 2026 | May 15, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 12, 2026 | Mar 12, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Feb 23, 2026 | Feb 19, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Regulation FD disclosure, Other events
|
Feb 19, 2026 | Feb 19, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 5, 2025 | Dec 5, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Unregistered share sale, Regulation FD disclosure, Other events
|
Oct 14, 2025 | Oct 14, 2025 |
| 8-K |
Current report
Material agreement
|
Aug 21, 2025 | Aug 18, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2025 | Aug 14, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jun 24, 2025 | Jun 23, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 23, 2025 | Jun 20, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 17, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 6, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 28, 2025 | May 28, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
May 22, 2025 | May 22, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 23, 2025 | Apr 23, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 27, 2025 | Mar 26, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2025 | Mar 13, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 25, 2025 | Feb 25, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Jan 13, 2025 | Jan 13, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 13, 2024 | Dec 12, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 11, 2024 | Dec 11, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 14, 2024 | Nov 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 28, 2024 | Oct 28, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 28, 2024 | Jun 26, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
May 30, 2024 | May 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 23, 2024 | May 23, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 25, 2024 | Apr 25, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 11, 2024 | Apr 11, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 9, 2024 | Apr 9, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 4, 2024 | Apr 4, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 28, 2024 | Mar 28, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 6, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Feb 13, 2024 | Feb 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 12, 2024 | Jan 12, 2024 |
| 8-K |
Current report
Other events
|
Jan 3, 2024 | Dec 28, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 15, 2023 | Dec 11, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 12, 2023 | Dec 12, 2023 |
| 8-K |
Current report
Exit or restructuring costs
|
Nov 28, 2023 | Nov 26, 2023 |
| 8-K |
Current report
Listing notice
|
Nov 21, 2023 | Nov 15, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 6, 2023 | Nov 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 6, 2023 | Nov 3, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 18, 2023 | Oct 18, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 26, 2023 | Sep 26, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 29, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 13, 2023 | Jun 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 8, 2023 | Jun 5, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 19, 2023 | May 19, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K | Current report | May 9, 2023 | May 8, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 17, 2023 | Apr 17, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2023 | Mar 30, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 22, 2023 | Feb 22, 2023 |
| 8-K |
Current report
Other events
|
Dec 6, 2022 | Dec 6, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 6, 2022 | Dec 6, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 29, 2022 | Nov 29, 2022 |
| 8-K |
Current report
Other events
|
Nov 18, 2022 | Nov 18, 2022 |
| 8-K |
Current report
Other events
|
Nov 14, 2022 | Nov 11, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2022 | Nov 10, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Oct 14, 2022 | Oct 13, 2022 |
| 8-K |
Current report
Officer or director change
|
Sep 7, 2022 | Sep 7, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2022 | Aug 5, 2022 |
| 8-K |
Current report
Officer or director change
|
Aug 1, 2022 | Jul 26, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 6, 2022 | Jun 4, 2022 |
| 8-K |
Current report
Other events
|
May 27, 2022 | May 26, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 29, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Mar 1, 2022 | Feb 24, 2022 |
| 8-K |
Current report
Other events
|
Feb 9, 2022 | Feb 3, 2022 |
| 8-K |
Current report
Officer or director change
|
Jan 31, 2022 | Jan 28, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2021 | Nov 12, 2021 |
| 8-K |
Current report
Results of operations
|
Sep 8, 2021 | Sep 8, 2021 |
| 8-K |
Current report
Other events
|
Aug 17, 2021 | Aug 13, 2021 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Jul 30, 2021 | Jul 29, 2021 |
Showing 85 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CADL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Needham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841387
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.